Amunix Pharmaceuticals snaps up $117m Series B

Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.

Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing. Viking Global Investors led the round.

Source: Press Release